



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/30

Date: 12th June 2026

To
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: Sudarshan
ISIN: INE00TV01023

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Allotment of 90,00,000 equity shares pursuant to exercise of Warrants allotted on preferential basis

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we wish to inform you that the Warrants Committee of the Board of Directors of the Company in their meeting held today i.e. Friday, 12th June, 2026, inter-alia, considered and approved the allotment of 90,00,000 equity shares of face value of Re.1/- each at an issue price of Rs.16.983 each (including a premium of Rs.15.983 each), consequent upon the conversion of 9,00,000 Warrants issued at an Issue Price of Rs.169.83 each, to the persons belonging to "Promoter Category", on preferential basis, upon receipt of balance amount aggregating to Rs.11,46,35,250/- at the rate of Rs.127.37 (Rupees One Hundred Twenty-Seven and Paise Thirty Seven Only) per warrant (being 75% of the issue price per warrant) from the allottees pursuant to the exercise of their rights of conversion into equity shares, as per the details given in "**Annexure-I**".

In accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("**SEBI ICDR Regulations**") the number of shares, paid-up capital per share and premium per share has been appropriately adjusted post sub-division undertaken by the Company with the approval of members of the Company vide postal ballot announced on 5th November, 2024.

The newly allotted equity shares shall rank pari-passu in all respects with the existing equity shares of the Company.

Consequently, the issued and paid-up capital of the Company stands increased to Rs.24,96,58,870/- consisting of 24,96,58,870 equity shares of Re.1/- each.

The disclosures required under Regulation 30 read with Schedule III of the SEBI Listing Regulations read along with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is provided in "**Annexure-II**".



Regd. Off. : 301, Aura Biplax, Above Kalyan Jewellers, S.V. Road, Borivali (West), Mumbai - 400092.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

The Meeting commenced at 7.00 pm and concluded at 7.15 pm.

Request you to take the same on your record.

Thanks and Regards

For, **Sudarshan Pharma Industries Limited**


Sachin Mehta
Joint Managing Director



Encl: As Above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

Annexure-I List of Allottees

Sr. no.	Name of the Allottees	No. of Warrants applied for conversion	Warrant exercise price being 75% of the issue price (in Rs.)	No. of equity shares allotted*
1	Mr. Hemal Vasantrai Mehta, Promoter	4,50,000	5,73,17,625	45,00,000
2	Mr. Sachin Vasantrai Mehta, Promoter	4,50,000	5,73,17,625	45,00,000
	TOTAL	9,00,000	11,46,35,250	90,00,000

*No. of equity shares allotted, upon conversion of warrants considered post sub-division of the Company with the approval of the members of the Company vide postal ballot announced on 5th November, 2024.

For, **Sudarshan Pharma Industries Limited**


Sachin Mehta
Joint Managing Director





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

Annexure-II

The details as required under Regulation 30 of SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are as under:

Sr. no.	Particulars	Description
1	Type of securities issued	Equity shares pursuant to conversion of warrants
2	Type of issuance	Preferential allotment
3	Total number of securities issued or the total amount for which the securities issued (approximately)	Allotment of 90,00,000 equity shares of face value of Re.1/- each at an issue price of Rs.16.983 each (including a premium of Rs.15.983 each), consequent upon the conversion of 9,00,000 Warrants issued at an Issue Price of Rs.169.83 each, to the persons belonging to "Promoter Category", on preferential basis, upon receipt of balance amount aggregating to Rs.11,46,35,250/- at the rate of Rs. 127.37 per warrant (being 75% of the issue price per warrant)
4	Name of the Allottee	Please Refer Annexure – I
5	Post allotment of securities - Outcome of the subscription Issue price / allotted price (in case of convertibles)	Pursuant to this allotment, the paid-up share capital of the Company stands increased to Rs.24,96,58,870/- consisting of 24,96,58,870 equity shares of Re.1/- each. Consequently, the Promoter / Promoter Group and Non-promoter shareholding stands at 58.93% and 41.07% respectively. Issue Price: Rs.169.83 Per warrant Subscription Price: Rs.42.46 per warrant (25% of Issue Price) Balance Price: Rs.127.37 per warrant (75% of Issue Price)





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

	Number of investors	2 (Two) – Please refer Annexure-I
6	In case of convertibles — intimation on conversion of securities or on lapse of the tenure of the instrument	<p>Conversion of 9,00,000 warrants into 90,00,000 fully paid-up equity shares of Re.1/- each at an issue price of Rs.16.983 each, consequent to change in nominal share value of the Company due to sub-division.</p> <p>The tenure of the warrants shall not exceed 18 months from the date of allotment. Each warrant shall carry a right to subscribe 1 (one) Equity Share per warrant, which may be exercised in one or more tranches during the period commencing from the date of allotment of warrants until the expiry of 18 months. An amount equivalent to 25% of the Warrant Issue Price has been received at the time of subscription and warrants were allotted. The balance 75% shall be payable by the Warrant holders on the exercise of Warrants.</p> <p>In the event that, a warrant holder does not exercise the warrants within a period of 18 months from the date of allotment of such warrants, the unexercised warrants shall lapse and the amount paid by the warrant holders on such Warrants shall stand forfeited by the Company.</p>

For, Sudarshan Pharma Industries Limited

Sachin Mehta
Joint Managing Director

